Overnight Market Wrap: 17 November

Overnight Market Wrap: 17 November

Key Points:

DJA and S&P500 soar to new all time highs

Moderna announces 94.5% efficacy in vaccine trials

Several US states announce further lockdown restrictions

As expected further good news was unleashed on the world yesterday as Moderna announced 94.5% efficacy on their vaccine trials, beating Pfizer’s 90% last week. That leaves room for another contender to try and beat the other two. The big plus with Moderna’s vaccine is that it doesn’t have the same storage and transportation headache that Pfizer has due to not needing to be stored at such a low temperature. Great news of course but the realisation as reiterated by Joe Biden is that we are a long way off being able to distribute these vaccines. A lot of people will die in the meantime unless better precautions are taken. New York, Illinois, Philadelphia and California have announced further restrictions to gatherings in a bid to get on top of recent escalation but many other states are still turning a blind eye. The UK has posted a 25% increase in deaths in the last 24 hours but France has seen a reduction in new cases proving that lockdown does work! Markets however aren’t too concerned with virus cases with both S&P500 and Dow Jones closing at record highs and WTI added another 3% ignoring the impact that further lockdowns may have in the US. Gold had a look at 1900 but was rejected to close unchanged on the day, overall the USD was weaker across the board with DXY falling back to 92.50. As expected the commodity currencies have fared well with AUD unaffected by RBA Lowe’s speech pushing back towards 0.7330. USD/CAD is now back below 1.31, benefiting from the move higher in Oil and NZD is looking to retest last week’s high above 0.6900. EUR/USD had a 50 pip range but closed where it opened around 1.1845 as Cable fell back from 1.3245 to 1.3195 with further negative Brexit headlines impacting. USD/JPY spiked to 105.10 on the Moderna news and in similar vein to EUR closed unchanged on the day around 104.60. Asia’s session ahead will be dominated by the release of RBA minutes sandwiched between Kent and DeBelle’s speeches but unlikely to discover anything here that we are unaware of. It’s possible there may be a reference to the AUD strength in the minutes so watch for a quick pullback, however if risk remains buoyant then AUD will move higher towards a retest of 0.7340 from last week. Tonight we get a look at US retail sales and yet again BoE Governor Bailey will be speaking, not expecting any surprises from him.

Trade the global markets with a broker that has integrity, honesty and transparency at its core


Market Wrap: 24 August 2023

Stocks Rally on Tech Optimism, Fed Rate Outlook:  Lackluster US, Europe economic data opens door for rate pause Nvidia’s bullish sales outlook prompts after-hours stock

Read More »

Market Wrap: 15 August 2023

Yuan Falls on PBOC Rate Cuts; Asian Stocks Mixed:  Japan’s economy shows resilience as growth beats estimates Economic woes mount in China as post-pandemic recovery

Read More »

Market Wrap: 11 August 2023

China Tech Pulls Asian Stocks Lower; Dollar Steady:  US core CPI posts smallest back-to-back increases in two years Daly says Fed has ‘more work to

Read More »

Market Wrap: 31 July 2023

Asian Stocks Echo US Rally on Soft Landing Hopes:  Yen declines after unscheduled Bank of Japan bond buying China manufacturing PMI data shows contraction in

Read More »

Market Wrap: 27 July 2023

Stocks Rise, Dollar Slips as Rates Peak in Sight:  ECB will raise rates by another quarter-point, survey shows US data Thursday include GDP, initial jobless

Read More »

This website is owned and operated by the Ox Securities group of companies, which include:
Ox Securities Pty Ltd registered address Level 37, 1 Macquarie Place, Sydney NSW 2000 Australia. AFSL 438402 ACN 163 551 602
Ox Securities Limited (SV) registered address Suite 305, Griffith Corporate Centre, Beachmont, Kingstown, St Vincent and the Grenadines
Risk Warning: The information contained on this website is general in nature and does not constitute advice or a recommendation to act upon the information or an offer. The information on this website does not take into account your personal objectives, circumstances, financial situations or needs. You are strongly recommended to seek independent professional advice before opening an account with us and/or acquiring our services/products. Ox Securities Limited (SV) do not accept applications from residents of the United States of America and Australia
Before you decide whether or not to invest any products referred to on this website, being over the counter (OTC) derivatives, it is important for you to read and consider our Financial Services Guide (FSG), Product Disclosure Statement (PDS), and Terms and Conditions (T&C), and ensure that you fully understand the risks involved. Fees, charges and commissions apply. OTC derivatives, including margin foreign exchange contracts and contract for differences, are leveraged products that carry a high level of risk to your capital. Trading is not suitable for everyone. You may incur losses that are substantially greater than your initial investment. You do not own, or have any rights to, the underlying assets which the OTC derivative is referring to. You should only trade with money you can afford to lose. There are also risks associated with online trading including, but not limited to, hardware and/or software failures, and disruptions to communication systems and internet connectivity.

Copyright © OxSecurities 2020. All rights reserved